MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.21.01485

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022

Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.

Funt Samuel A, Lattanzi Michael, Whiting Karissa, Al-Ahmadie Hikmat, Quinlan Colleen, Teo Min Yuen, Lee Chung-Han, Aggen David, Zimmerman Danielle, McHugh Deaglan, Apollo Arlyn, Durdin Trey D, Truong Hong, Kamradt Jeffrey, Khalil Maged, Lash Bradley, Ostrovnaya Irina, McCoy Asia S, Hettich Grace, Regazzi Ashley, Jihad Marwah, Ratna Neha, Boswell Abigail, Francese Kaitlyn, Yang Yuanquan, Folefac Edmund, Herr Harry W, Donat S Machele, Pietzak Eugene, Cha Eugene K, Donahue Timothy F, Goh Alvin C, Huang William C, Bajorin Dean F, Iyer Gopa, Bochner Bernard H, Balar Arjun V, Mortazavi Amir, Rosenberg Jonathan E

Клиническое исследование II фазыСтатьяМногоцентровое исследованиеПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: Neoadjuvant gemcitabine and cisplatin (GC) followed by radical cystectomy (RC) is standard for patients with muscle-invasive bladder cancer (MIBC). On the basis of the activity of atezolizumab (A) in metastatic BC, we tested neoadjuvant GC plus A for MIBC.

METHODS

Eligible patients with MIBC (cT2-T4aN0M0) received a dose of A, followed 2 weeks later by GC plus A every 21 days for four cycles followed 3 weeks later by a dose of A before RC. The primary end point was non-muscle-invasive downstaging to < pT2N0.

RESULTS

Of 44 enrolled patients, 39 were evaluable. The primary end point was met, with 27 of 39 patients (69%) < pT2N0, including 16 (41%) pT0N0. No patient with < pT2N0 relapsed and four (11%) with ≥ pT2N0 relapsed with a median follow-up of 16.5 months (range: 7.0-33.7 months). One patient refused RC and two developed metastatic disease before RC; all were considered nonresponders. The most common grade 3-4 adverse event (AE) was neutropenia (n = 16; 36%). Grade 3 immune-related AEs occurred in five (11%) patients with two (5%) requiring systemic steroids. The median time from last dose of chemotherapy to surgery was 7.8 weeks (range: 5.1-17 weeks), and no patient failed to undergo RC because of AEs. Four of 39 (10%) patients had programmed death-ligand 1 (PD-L1)-positive tumors and were all < pT2N0. Of the patients with PD-L1 low or negative tumors, 23 of 34 (68%) achieved < pT2N0 and 11 of 34 (32%) were ≥ pT2N0 (P = .3 for association between PD-L1 and < pT2N0).

CONCLUSION

Neoadjuvant GC plus A is a promising regimen for MIBC and warrants further study. Patients with < pT2N0 experienced improved relapse-free survival. The PD-L1 positivity rate was low compared with published data, which limits conclusions regarding PD-L1 as a predictive biomarker.

Для цитирования: Funt Samuel A, Lattanzi Michael, Whiting Karissa, Al-Ahmadie Hikmat, Quinlan Colleen, Teo Min Yuen, Lee Chung-Han, Aggen David, Zimmerman Danielle, McHugh Deaglan, Apollo Arlyn, Durdin Trey D, Truong Hong, Kamradt Jeffrey, Khalil Maged, Lash Bradley, Ostrovnaya Irina, McCoy Asia S, Hettich Grace, Regazzi Ashley, Jihad Marwah, Ratna Neha, Boswell Abigail, Francese Kaitlyn, Yang Yuanquan, Folefac Edmund, Herr Harry W, Donat S Machele, Pietzak Eugene, Cha Eugene K, Donahue Timothy F, Goh Alvin C, Huang William C, Bajorin Dean F, Iyer Gopa, Bochner Bernard H, Balar Arjun V, Mortazavi Amir, Rosenberg Jonathan E. Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022. DOI: 10.1200/jco.21.01485.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.